VÄSTRA FRÖLUNDA, Sweden--(BUSINESS WIRE)--Jimmy Jones has been employed as President and Head of Marketing at the Artimplant (STO:ARTIB) subsidiary in the USA. Jones has more than 18 years' experience of the US orthopedics market and will bring considerable knowledge and expertise to Artimplant.
As part of the investment to reinforce the US organisation, two persons with long experience from the orthopedics market have been employed and at the same time three people have left the organization.
Administration and marketing support have been brought together at Artimplant's newly opened office in Denver Colorado, which will offer significantly better support to the market and result in greater cost efficiency.
Kjell Thörnbring, Artimplant CEO comments:
"With the new team in place we are firmly convinced that we will see positive developments on the US market, which is vitally important for Artimplant."
Further information at www.artimplant.com where one also can subscribe to future press releases; www.artimplant.com/investors-media/subscribe-to-press-releases.html
Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral applications.
Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on December 2 at 11:00 AM (Swedish time).
This information was brought to you by Cision http://www.cisionwire.com